Proqr Therapeutics vs Scynexis
Proqr Therapeutics and Scynexis are similar in size: $18.0m and $20.6m of revenue in their latest fiscal years. Scynexis grew faster (449.9% against -12.1%). Scynexis kept more of each dollar of sales as profit: a net margin of -41.8% against -265.2%. Scynexis carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Proqr TherapeuticsPRQR, 2025 | ScynexisSCYX, 2025 |
|---|---|---|
| Revenue | $18.0m | $20.6m |
| Revenue growth | -12.1% | 449.9% |
| Net income | −$47.7m | −$8.6m |
| Operating margin | -273.1% | -78.0% |
| Net margin | -265.2% | -41.8% |
| Return on equity | -63.8% | -16.5% |
| Free cash flow | −$60.8m | −$5.3m |
| Cash | $108m | $21.3m |
| Total debt | $5.7m | $0 |
| Debt to equity | 9.9% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 18 |
| Market value | $144m | $39.1m |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 0 sales |